MCID: CHN012
MIFTS: 56

Chondrosarcoma

Categories: Genetic diseases, Rare diseases, Bone diseases, Cancer diseases

Aliases & Classifications for Chondrosarcoma

MalaCards integrated aliases for Chondrosarcoma:

Name: Chondrosarcoma 53 12 72 49 55 71 28 13 51 41 14 69
Primary Chondrosarcoma of the Bone 12
Chondrosarcoma of Bone 12
Chdsa 71

Characteristics:

Orphanet epidemiological data:

55
chondrosarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

OMIM:

53
Inheritance:
autosomal recessive


HPO:

31
chondrosarcoma:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 55  
Rare bone diseases


External Ids:

OMIM 53 215300
Disease Ontology 12 DOID:3371
MeSH 41 D002813
NCIt 46 C2946 C7155
Orphanet 55 ORPHA55880
MESH via Orphanet 42 D002813
UMLS via Orphanet 70 C0008479
ICD10 via Orphanet 33 C49.9
MedGen 39 C0008479
SNOMED-CT via HPO 65 258211005

Summaries for Chondrosarcoma

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 55880Disease definitionChondrosarcoma is a malignant bone tumor arising from cartilaginous tissue, most frequently occuring at the ends of the femur and tibia, the proximal end of the humerus and the pelvis; and presenting with a palpable mass and progressive pain. Chondrosarcoma is usually slow growing at low histological grades and can be well managed by intralesional curettage or en-block wide resection.Visit the Orphanet disease page for more resources. Last updated: 7/21/2015

MalaCards based summary : Chondrosarcoma, also known as primary chondrosarcoma of the bone, is related to myxoid chondrosarcoma and intracranial chondrosarcoma. An important gene associated with Chondrosarcoma is EXT1 (Exostosin Glycosyltransferase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Citrate cycle (TCA cycle). The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast.

UniProtKB/Swiss-Prot : 71 Chondrosarcoma: A malignant neoplasm derived from cartilage cells. Chondrosarcomas range from slow-growing non-metastasizing lesions to highly aggressive metastasizing sarcomas.

Disease Ontology : 12 A connective tissue cancer that has material basis in cells derived from transformed cells that produce cartilage.

Wikipedia : 72 Chondrosarcoma is a cancer composed of cells derived from transformed cells that produce cartilage.... more...

Description from OMIM: 215300

Related Diseases for Chondrosarcoma

Diseases in the Chondrosarcoma family:

Localized Chondrosarcoma

Diseases related to Chondrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 myxoid chondrosarcoma 33.9 EWSR1 MTAP NR4A3 TAF15
2 intracranial chondrosarcoma 33.8 IDH1 IDH2
3 clear cell chondrosarcoma 33.7 EXT2 SPARC
4 chondrosarcoma, extraskeletal myxoid 33.5 ENO2 EWSR1 NR4A3 TAF15 TFG
5 extraosseous chondrosarcoma 33.4 ENO2 EWSR1 TAF15 TFG
6 periosteal chondrosarcoma 33.1 EXT1 IDH1 IDH2 NCOA2 PTHLH
7 multiple enchondromatosis, maffucci type 32.3 EXT1 EXT2 IDH1 IDH2
8 exostoses, multiple, type i 32.2 EXT1 EXT2
9 enchondroma 31.4 IDH1 IDH2
10 osteochondroma 30.8 EXT1 EXT2 PTHLH
11 chondroblastic osteosarcoma 30.5 IDH1 IDH2
12 enchondromatosis, multiple, ollier type 30.0 EXT1 EXT2 IDH1 IDH2 PTHLH
13 ewing sarcoma 29.7 ENO2 EWSR1 MMP1 NR4A3 TAF15
14 mesenchymal chondrosarcoma 12.4
15 bone chondrosarcoma 12.2
16 adult mesenchymal chondrosarcoma 12.1
17 adult myxoid chondrosarcoma 12.1
18 extraskeletal mesenchymal chondrosarcoma 12.1
19 localized chondrosarcoma 12.0
20 juxtacortical chondrosarcoma 12.0
21 pediatric mesenchymal chondrosarcoma 11.8
22 pediatric myxoid chondrosarcoma 11.8
23 adult extraosseous chondrosarcoma 11.8
24 chondroid chordoma 11.2
25 exostoses, multiple, type ii 11.2
26 bone cancer 10.9
27 bizzare parosteal osteochondromatous proliferation 10.9
28 dysplasia epiphysealis hemimelica 10.6 EXT1 EXT2
29 interval angle-closure glaucoma 10.5 IDH1 IDH2
30 adult oligodendroglioma 10.5 IDH1 IDH2
31 glioma susceptibility 1 10.5 IDH1 IDH2
32 anaplastic oligodendroglioma 10.5 IDH1 IDH2
33 cytogenetically normal acute myeloid leukemia 10.5 IDH1 IDH2
34 intraductal papilloma 10.4 IDH1 IDH2
35 hereditary multiple osteochondromas 10.4 EXT1 EXT2
36 juxtacortical chondroma 10.4 EWSR1 EXT1 PTHLH
37 adult astrocytic tumour 10.3 IDH1 IDH2 MMP1
38 small cell osteogenic sarcoma 10.3 ENO2 EWSR1
39 chordoma 10.3
40 periostitis 10.3
41 spindle cell hemangioma 10.3 IDH1 IDH2
42 sarcoma 10.3
43 orbital cancer 10.3 ENO2 EWSR1
44 askin's tumor 10.3 ENO2 EWSR1
45 tooth ankylosis 10.2 PTHLH SPARC
46 synovial chondromatosis 10.2
47 connective tissue cancer 10.2 ENO2 EWSR1 EXT1
48 kidney rhabdoid cancer 10.2 ENO2 EWSR1
49 cauda equina neoplasm 10.2 ENO2 EWSR1
50 cervicitis 10.2

Graphical network of the top 20 diseases related to Chondrosarcoma:



Diseases related to Chondrosarcoma

Symptoms & Phenotypes for Chondrosarcoma

Symptoms via clinical synopsis from OMIM:

53
Skel:
chondrosarcoma


Clinical features from OMIM:

215300

Human phenotypes related to Chondrosarcoma:

31
# Description HPO Frequency HPO Source Accession
1 chondrosarcoma 31 HP:0006765

Drugs & Therapeutics for Chondrosarcoma

Drugs for Chondrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
8
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
9
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Alkylating Agents Phase 3,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
14 Isophosphamide mustard Phase 3,Phase 2 0
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
16 Analgesics Phase 3,Phase 1,Phase 2
17 Liver Extracts Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
19 Adjuvants, Anesthesia Phase 3
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Central Nervous System Depressants Phase 3
25 Narcotics Phase 3
26 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
27 Anti-Allergic Agents Phase 3
28 Antipruritics Phase 3
29 Dermatologic Agents Phase 3
30 Histamine Antagonists Phase 3
31 Histamine H1 Antagonists Phase 3
32
Histamine Phosphate Phase 3 51-74-1 65513
33 Neurotransmitter Agents Phase 3
34
Serotonin Phase 3 50-67-9 5202
35 Serotonin Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Cola Nutraceutical Phase 3,Phase 1
38
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
39
Metformin Approved Phase 1, Phase 2 657-24-9 4091 14219
40
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
41
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
42
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
43
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
44
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
45
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
46
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
47
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
48
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
49
Dactinomycin Approved, Investigational Phase 2 50-76-0 457193 2019
50
Epirubicin Approved Phase 2 56420-45-2 41867

Interventional clinical trials:

(show top 50) (show all 82)

# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base Recruiting NCT01182753 Phase 3
6 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
7 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
8 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
10 Proton Radiation for Chordomas and Chondrosarcomas Unknown status NCT01449149 Phase 1, Phase 2
11 Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Unknown status NCT02496741 Phase 1, Phase 2 Metformin and chloroquine combination
12 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
13 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
14 A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Completed NCT01310816 Phase 2 IPI-926;Placebo Arm
15 S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone Completed NCT00096213 Phase 2
16 S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma Completed NCT00107419 Phase 2 pemetrexed disodium
17 Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine Completed NCT00592748 Phase 1, Phase 2
18 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride
19 A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas Completed NCT00401388 Phase 2 Perifosine
20 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
21 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Completed NCT01560260 Phase 2 Linsitinib
22 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2 AG-221
23 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
24 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
27 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
28 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
29 Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma Completed NCT00003308 Phase 2
30 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
31 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
32 A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Completed NCT00948961 Phase 1, Phase 2
33 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
34 Alanosine in Treating Patients With Cancer Completed NCT00062283 Phase 2 L-alanosine
35 Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma Recruiting NCT02066285 Phase 2 Pazopanib
36 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
37 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
38 A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Recruiting NCT02389244 Phase 2 Regorafenib;Placebo
39 Proton or Photon RT for Retroperitoneal Sarcomas Recruiting NCT01659203 Phase 1, Phase 2
40 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
41 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Recruiting NCT02301039 Phase 2 Pembrolizumab
42 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
43 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
44 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Active, not recruiting NCT01330966 Phase 2 pazopanib
45 Proton Beam Therapy for Chondrosarcoma Active, not recruiting NCT00496522 Phase 2
46 Imatinib in Patients With Desmoid Tumor and Chondrosarcoma Active, not recruiting NCT00928525 Phase 2 Imatinib Mesylate
47 Vismodegib in Treating Patients With Advanced Chondrosarcomas Active, not recruiting NCT01267955 Phase 2 Vismodegib
48 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
49 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
50 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg Active, not recruiting NCT00589121 Phase 2 Chemotherapy

Search NIH Clinical Center for Chondrosarcoma

Cochrane evidence based reviews: chondrosarcoma

Genetic Tests for Chondrosarcoma

Genetic tests related to Chondrosarcoma:

# Genetic test Affiliating Genes
1 Chondrosarcoma 28 EXT1

Anatomical Context for Chondrosarcoma

MalaCards organs/tissues related to Chondrosarcoma:

38
Bone, Lung, Breast, Brain, Kidney, Endothelial, Liver

Publications for Chondrosarcoma

Articles related to Chondrosarcoma:

(show top 50) (show all 1552)
# Title Authors Year
1
18F-FDG PET/CT Findings of Mesenchymal Chondrosarcoma of the Orbit. ( 29215408 )
2018
2
Osteosarcoma, Chondrosarcoma, and Chordoma. ( 29220289 )
2018
3
Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance. ( 29361725 )
2018
4
Diagnostic Role of Intraoperative Imprint Cytology in an Unusual Case of Chondrosarcoma Presenting as Acute Onset Stridor. ( 29403179 )
2018
5
Mesenchymal Chondrosarcoma of the Lacrimal Gland. ( 29342030 )
2018
6
Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27. ( 29397960 )
2018
7
Mosaic-pattern dedifferentiation in liposarcoma and chondrosarcoma: imaging features of an uncommon form of dedifferentiation. ( 29362843 )
2018
8
Primary extraskeletal mesenchymal chondrosarcoma arising from the iliac vein. ( 29332118 )
2018
9
18F-FDG PET/CT in Diagnostic and Prognostic Evaluation of Patients With Suspected Recurrence of Chondrosarcoma. ( 29261626 )
2018
10
Tumour Volume and Dose Influence Outcome after Surgery and High-dose Photon Radiotherapy for Chordoma and Chondrosarcoma of the Skull Base and Spine. ( 29402600 )
2018
11
Analysis of IL6-protein complexes in chondrosarcoma. ( 29399342 )
2018
12
Periosteal mesenchymal chondrosarcoma of the tibia. ( 29397433 )
2018
13
INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. ( 29327709 )
2018
14
Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study. ( 29316907 )
2018
15
Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma. ( 29158368 )
2018
16
Clinicopathological and histological behavior of mesenchymal chondrosarcoma involving maxilla. ( 28479701 )
2017
17
Intraspinal mesenchymal chondrosarcoma: report of a pediatric case and literature review. ( 29143958 )
2017
18
Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001-2011). ( 28420036 )
2017
19
Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients. ( 29044531 )
2017
20
p63 protects chondrosarcoma malignancies mainly by enhancing the expression of PTEN. ( 29441939 )
2017
21
Primary pulmonary myxoid sarcoma, a potential mimic of metastatic extraskeletal myxoid chondrosarcoma. ( 29110880 )
2017
22
Chondrosarcoma of the Epiglottis: A Case Report and Literature Review. ( 28822621 )
2017
23
Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study. ( 28884356 )
2017
24
Clear cell chondrosarcoma proximal femur with secondary aneurysmal component - A rarity. ( 28360507 )
2017
25
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma. ( 28860121 )
2017
26
Curious case of extraskeletal myxoid chondrosarcoma. ( 28360467 )
2017
27
Severe Hypocalcemia in a Patient with Recurrent Chondrosarcoma. ( 28717079 )
2017
28
Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. ( 28834325 )
2017
29
Expression of MMPs is dependent on the activity of mitogen-activated protein kinase in chondrosarcoma. ( 28035378 )
2017
30
Chondrosarcoma mimicking an adnexal mass: A very rare case report. ( 28913138 )
2017
31
Management of Nasal Septum Chondrosarcoma Occurring in Elderly: A Case Report. ( 28948117 )
2017
32
Type II cGMP-dependent protein kinase negatively regulates fibroblast growth factor signaling by phosphorylating Raf-1 at serine 43 in rat chondrosarcoma cells. ( 28057484 )
2017
33
Phalangeal chondrosarcoma: A rare presentation with an unusual biological behavior. ( 28465204 )
2017
34
Extraskeletal orbital mesenchymal chondrosarcoma: surgical approach and mini review. ( 28258179 )
2017
35
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. ( 28552826 )
2017
36
WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis. ( 28465477 )
2017
37
Chondrosarcoma: Extrinsic Compression of the Right Ventricle and Pericardial Effusion. ( 28709860 )
2017
38
Low-grade chondrosarcoma of the cricoid cartilage: a case report and review of the literature. ( 28756568 )
2017
39
Amphiregulin enhances VEGF-A production in human chondrosarcoma cells and promotes angiogenesis by inhibiting miR-206 via FAK/c-Src/PKCI' pathway. ( 27826039 )
2017
40
Conservative surgery for laryngeal chondrosarcoma: a review of the most recently proposed approaches. ( 28059901 )
2017
41
Primary chondrosarcoma of the trachea with extensive extralumenal growth. ( 28444377 )
2017
42
Primary extraskeletal myxoid chondrosarcoma of bone: Report of three cases and review of the literature. ( 28249774 )
2017
43
Juxtacortical Mandibular Chondrosarcoma during pregnancy: A case report. ( 28512553 )
2017
44
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. ( 27696380 )
2017
45
Next generation sequencing of extraskeletal myxoid chondrosarcoma. ( 28423517 )
2017
46
Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. ( 28852958 )
2017
47
Primary Spinal Intradural Mesenchymal Chondrosarcoma with Several Local Regrowths Treated with Osteoplastic Laminotomies: A Case Report. ( 28825035 )
2017
48
Parasellar Chondrosarcoma in Three Young Patients: A Diagnosis of Caution. ( 28936090 )
2017
49
Extraskeletal mesenchymal chondrosarcoma at unusual location involving spleen and kidney with review of literature. ( 28631650 )
2017
50
Reconstruction with iliac pedestal cup and proximal femur tumor prosthesis after wide resection of chondrosarcoma - 10-year follow-up results. ( 29234663 )
2017

Variations for Chondrosarcoma

UniProtKB/Swiss-Prot genetic disease variations for Chondrosarcoma:

71
# Symbol AA change Variation ID SNP ID
1 EXT1 p.Asn316Ser VAR_012820

ClinVar genetic disease variations for Chondrosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EXT1 NM_000127.2(EXT1): c.528_535delCAAAGTGC (p.Lys177Glufs) deletion Pathogenic rs587776540 GRCh37 Chromosome 8, 119122751: 119122758

Cosmic variations for Chondrosarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM28749 IDH1 bone,femur,chondrosarcoma,conventional c.394C>G p.R132G 13
2 COSM28747 IDH1 bone,femur,chondrosarcoma,conventional c.394C>T p.R132C 13
3 COSM28750 IDH1 bone,tibia,chondrosarcoma,conventional c.395G>T p.R132L 13
4 COSM28746 IDH1 bone,humerus,chondrosarcoma,NS c.395G>A p.R132H 13
5 COSM28748 IDH1 bone,humerus,chondrosarcoma,NS c.394C>A p.R132S 13
6 COSM485 HRAS bone,femur,chondrosarcoma,conventional c.35G>C p.G12A 13
7 COSM480 HRAS bone,femur,chondrosarcoma,conventional c.34G>A p.G12S 13

Copy number variations for Chondrosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 110025 17 31160600 31198351 Translate TAF15 Chondrosarcoma

Expression for Chondrosarcoma

Search GEO for disease gene expression data for Chondrosarcoma.

Pathways for Chondrosarcoma

GO Terms for Chondrosarcoma

Biological processes related to Chondrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cartilage development GO:0051216 9.58 CNMD MMP13 SOX9
2 skeletal system development GO:0001501 9.56 CNMD EXT1 PTHLH SOX9
3 2-oxoglutarate metabolic process GO:0006103 9.48 IDH1 IDH2
4 negative regulation of chondrocyte differentiation GO:0032331 9.46 PTHLH SOX9
5 heparan sulfate proteoglycan biosynthetic process GO:0015012 9.43 EXT1 EXT2
6 isocitrate metabolic process GO:0006102 9.37 IDH1 IDH2
7 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process GO:0015014 9.32 EXT1 EXT2
8 cellular polysaccharide biosynthetic process GO:0033692 9.16 EXT1 EXT2
9 glyoxylate cycle GO:0006097 8.96 IDH1 IDH2
10 ossification GO:0001503 8.92 EXT1 EXT2 SOX9 SPARC

Molecular functions related to Chondrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 acetylglucosaminyltransferase activity GO:0008375 9.4 EXT1 EXT2
2 heparan sulfate N-acetylglucosaminyltransferase activity GO:0042328 9.32 EXT1 EXT2
3 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity GO:0050508 9.26 EXT1 EXT2
4 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity GO:0050509 9.16 EXT1 EXT2
5 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH1 IDH2
7 metal ion binding GO:0046872 10.11 ENO2 EWSR1 EXT1 EXT2 IDH1 IDH2

Sources for Chondrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....